Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / XERS - Xeris Biopharma reaches Phase 2 milestone by dosing first participant in hypothyroidism study

XERS - Xeris Biopharma reaches Phase 2 milestone by dosing first participant in hypothyroidism study

Xeris Pharmaceuticals Inc.

--News Direct--

Xeris Biopharma Chairman & CEO Paul Edick joins Natalie Stoberman from the Proactive newsroom to share the latest milestone of having its first participant being dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism.

Edick says this milestone is crucial considering initiating such studies is challenging and time-consuming. He adds that Xeris Biopharma aims to compare its stable therapy with existing treatments in the market, which are often poorly tolerated or improperly absorbed. Xeris' innovative liquid stable formulation offers a once-weekly subcutaneous injection, bypassing the gastrointestinal tract and providing consistent blood levels.

The ongoing clinical study will need to dose around 40 to 50 patients before moving on to Phase 3 of the program.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/xeris-biopharma-reaches-phase-2-milestone-by-dosing-first-participant-in-hypothyroidism-study-778880498

Stock Information
Company Name: Xeris Pharmaceuticals Inc.
Stock Symbol: XERS
Market: NASDAQ
Menu
XERS XERS Quote XERS Short XERS News XERS Articles XERS Message Board
Get XERS Alerts

News, Short Squeeze, Breakout and More Instantly...